Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04904484
  4. Details
NCT04904484 Clinical Trial

A Safety Assessment of the iZephyr Hood for NIV in COVID-19 Patients

Covid19 Clinical Trial

— iZephyr  

Official title:
A Safety Assessment of the iZephyr Hood for Non Invasive Ventilation in COVID-19 Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04904484
Other study ID # 292573
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date October 1, 2025

Study information
Verified date March 2024
Source Imperial College Healthcare NHS Trust
Contact Priscilla Humado
Phone 02033137306
Email priscilla.humado1@nhs.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a safety assessment of the iZephyr hood a novel aerosol removal device in patients receiving non invasive ventilation for COVID-19.

Description:

Demonstrate that safety and suitability of the iZephyr Hood in patients receiving non-invasive ventilation (NIV) or high flow oxygen therapy (HFOT). Determine the user acceptability of the iZephyr Hood in patients receiving NIV and HFOT. Determine the reduction in aerosol spread of COVID-19 viral particles when using the Zephyr hood in patients using non-invasive ventilation or high flow oxygen.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 30
Est. completion date October 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Adult COVID-19 negative patients who are requiring non-invasive ventilation (phase II) Adult COVID-19 positive patients who are requiring non-invasive ventilation (Phase III) Exclusion Criteria: Patients under the age of 18 years or those lacking capacity

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• iZephyr hood
Assessment of an aerosol containment device

Locations
Country Name City State
n/a

Sponsors (3)
Lead Sponsor Collaborator
Imperial College Healthcare NHS Trust Imperial College London, Mercedes AMG PETRONAS Formula One Team

Outcome
Type Measure Description Time frame Safety issue
Primary Determine the background concentration of SARS-Co-V2 around COVID patients receiving NIV Air and surface sampling for SARS Co-V2 around COVID patients receiving non invasive ventilation or high flow oxygen therapy. 3 month
Primary Determine the background concentration of SARS-Co-V2 when the iZephyr hood is in use Air and surface sampling for SARS Co-V2 around COVID patients receiving non invasive ventilation or high flow oxygen therapy inside an iZephyr hood. 12 months
Primary Impact of iZephyr hood on environmental SARS Co-V2 contamination Determine if there is a change in the concentration of SARS-Co-V2 virus on the surfaces and in the air samples surrounding a COVID-19 positive patient whilst using the iZephyr compared to when not using the iZephyr. 12 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3